Please ensure Javascript is enabled for purposes of website accessibility
network member

Washington, D.C.

About Network Member

Currently Enrolling

HCRN-GU23-651

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Cancer areas:Kidney
Froedtert & the Medical College of Wisconsin
Georgetown Lombardi Comprehensive Cancer Center
Penn State Cancer Institute
University of North Carolina Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
Georgetown Lombardi Comprehensive Cancer Center
Medical University of South Carolina
New York University Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
University of New Mexico Comprehensive Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Virginia Commonwealth University
Enrollment Closed

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)
Cancer areas:Kidney
Beth Israel Deaconess Medical Center
Columbia University Irving Medical Center
Dana-Farber Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
John Theurer Cancer Center at Hackensack Meridian Health
Moores Cancer Center at UC San Diego
Penn Medicine Abramson Cancer Center
The Ohio State University
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Weill Cornell Medicine
Winship Cancer Institute of Emory University
Yale Cancer Center
Currently Enrolling

HCRN-LUN21-530

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)
Cancer areas:Lung
Barbara Ann Karmanos Cancer Center
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Enrollment Closed

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Cancer areas:Breast
Dana-Farber Cancer Institute
Duke Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The University of Chicago Medicine Comprehensive Cancer Center
UC San Francisco
University of Alabama at Birmingham Comprehensive Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Enrollment Closed

HCRN-MEL17-309

Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma
Cancer areas:Melanoma
Columbia University Irving Medical Center
Georgetown Lombardi Comprehensive Cancer Center
MD Anderson Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
UC San Francisco